Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 64 across all filing types
Latest filing 2026-04-16 Annual Report (ESEF)
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2025
Annual Report (ESEF) Classification · 1% confidence FY 2025
2026-04-16 Swedish
Notice of Annual General Meeting in Cinclus Pharma Holding AB (publ)
AGM Information Classification · 1% confidence The document is a press release titled “NOTICE OF ANNUAL GENERAL MEETING” for Cinclus Pharma Holding AB (publ), detailing the date, time, location, participation instructions, agenda items, nomination committee proposals, and board proposals for the upcoming Annual General Meeting. It is clearly an invitation/notice of the AGM rather than the meeting minutes, proxy materials, or a full annual report. This matches the definition of “AGM Information” (Code: AGM-R).
2026-04-16 English
Kallelse till årsstämma i Cinclus Pharma Holding AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal “Kallelse till årsstämma” (notice of Annual General Meeting) including registration details, agenda items, proposals from the board and nomination committee, voting instructions and proxy information. This is not the meeting results or an annual report itself, but rather materials sent to shareholders to provide information ahead of the AGM and solicit votes. It therefore fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-16 Swedish
Cinclus Pharma ingår ett finansieringsavtal om 28 miljoner EUR
Capital/Financing Update Classification · 1% confidence The document is a press release from Cinclus Pharma announcing a new structured credit agreement (financing) of 28 million EUR with Claret Capital Partners. It details the terms of the financing, including tranches, interest rates, conversion rights, and warrants. This falls under the category of company fundraising and financing activities. While it mentions the issuance of shares/warrants, the primary purpose is the announcement of a major financing deal, which aligns best with the 'CAP' (Capital/Financing Update) category.
2026-03-13 Swedish
Cinclus Pharma Enters into EUR 28 Million Financing Agreement
Capital/Financing Update Classification · 1% confidence The document is a press release from Cinclus Pharma announcing a new EUR 28 million financing agreement with Claret Capital Partners. It details the structure of the financing (tranches, convertibles, warrants, interest rates, and security). This falls under the category of capital and financing updates as it describes the company's fundraising and capital structure changes.
2026-03-13 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Cinclus Pharma covering the period January to December 2025. It contains detailed financial statements, including income statements, balance sheets, cash flow analysis, and notes to the financial information, which distinguishes it from a simple earnings release or a report publication announcement. It is a comprehensive financial report for a period shorter than a full fiscal year (as it is a Q4/Year-end interim report). Q4 2025
2026-02-18 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.